Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Depression remission

May be associated with higher depression remission rates than SSRIs... [Pg.509]

Antipsychotic medications are indicated in the treatment of acute and chronic psychotic disorders. These include schizophrenia, schizoaffective disorder, and manic states occurring as part of a bipolar disorder or schizoaffective disorder. The co-adminstration of antipsychotic medication with antidepressants has also been shown to increase the remission rate of severe depressive episodes that are accompanied by psychotic symptoms. Antipsychotic medications are frequently used in the management of agitation associated with delirium, dementia, and toxic effects of both prescribed medications (e.g. L-dopa used in Parkinson s disease) and illicit dtugs (e.g. cocaine, amphetamines, andPCP). They are also indicated in the management of tics that result from Gilles de la Tourette s syndrome, and widely used to control the motor and behavioural manifestations of Huntington s disease. [Pg.183]

Symptoms of a major depressive episode usually develop over days to weeks, but mild depressive and anxiety symptoms may last for weeks to months prior to the onset of the full syndrome. Left untreated, major depressive episodes typically last 6 months or more, but a minority of patients experience chronic episodes that can last for at least 2 years. Approximately two-thirds of patients will recover fully from major depressive episodes and return to usual mood and full functioning, whereas the other third will have partial remission and may continue to experience detrimental effects.3... [Pg.572]

Bipolar disorder is a mood disorder characterized by one or more episodes of mania or hypomania, often with a history of one or more major depressive episodes.1 It is a chronic illness with a course characterized by relapses and improvements or remissions. Mood episodes can be manic, depressed, or mixed. They can be separated by long periods of stability or can cycle... [Pg.585]

O The goals of therapy for GAD are to acutely reduce the severity and duration of anxiety symptoms and restore overall functioning. The long-term goal in GAD is to achieve and maintain remission. With a positive response to treatment, patients with GAD and comorbid depression should have minimal depressive symptoms. [Pg.609]

The main objectives of treatment are to reduce the severity and frequency of panic attacks, reduce anticipatory anxiety and agoraphobic behavior, and minimize symptoms of depression or other comorbid disorders.48 The long-term goal is to achieve and sustain remission. [Pg.614]

Arias, B., Catalan, R. et al. (2003). 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. /. Clin. Psychopharmacol, 23(6), 563-7. [Pg.34]

Using this very strict criterion of remission, the STAR D researchers reported that 37 per cent of the patients in the trial recovered from depression on the first medication they were given. Another 19 per cent of the full group of patients recovered on the second medication, 6 per cent on the third and 5 per cent on the fourth. Altogether, 67 per cent of the patients recovered. However, the remission of symptoms turned out to be only temporary for many - approximately half of the patients who recovered relapsed within a year. [Pg.59]

There is only one group of research subjects in whom rapid depletion of serotonin sometimes produces clinical depression. These are depressed patients in remission who are currently taking SSRIs. About half of these patients relapse when serotonin is depleted. Note that this only happens if they are still taking antidepressant medication. If they have stopped medication, depleting... [Pg.91]

In clinical psychiatric terms, the affective disorders can be subdivided into unipolar and bipolar disorders. Unipolar depression is also known as psychotic depression, endogenous depression, idiopathic depression and major depressive disorder. Bipolar disorder is now recognised as being heterogeneous bipolar disorder I is equivalent to classical manic depressive psychosis, or manic depression, while bipolar disorder II is depression with hypomania (Dean, 2002). Unipolar mania is where periods of mania alternate with periods of more normal moods. Seasonal affective disorder (SAD) refers to depression with its onset most commonly in winter, followed by a gradual remission in spring. Some milder forms of severe depression, often those with an identifiable cause, may be referred to as reactive or neurotic depression. Secondary depression is associated with other illnesses, such as neuro-degenerative or cardiovascular diseases, and is relatively common. [Pg.172]

Approximately 30-40% of patients will not respond to a given antidepressant and 60-75% may fail to achieve complete remission [16]. Consequently, in its least restricted definition, treatment resistance could be detected in the majority of depressed patients under treatment. Moreover, prior treatment failure negatively influences the response to subsequent antidepressant treatment, decreasing the odds of treatment response by a factor of 15-20% for each failed treatment [17]. The delayed onset of symptom relief (which takes three to eight weeks to occur) and the presence of adverse drug reactions contribute significantly to low treatment compliance. [Pg.386]

Souetre, E., Salvati, E., Wehr, T. A. et al. Twenty-four-hour profiles of body temperature and plasma TSH in bipolar patients during depression and during remission and in normal control subjects. Am. J. Psychiatry 145 1133-1137, 1988. [Pg.907]

The STAR D study showed that one in three depressed patients who previously did not achieve remission with an antidepressant became symptom-free with the help of an additional medication (e.g., bupropion sustained release), and one in four achieved remission after switching to a different antidepressant (e.g., venlafaxine XR). [Pg.808]

Major depression varies greatly from person to person. Therefore, DSM-IV uses course and descriptive specifiers to further describe the disorder in each individual. The course specifiers quantitatively describe the long-term history of the illness. Patterns of episode recurrence and remission are delineated by these specifiers. [Pg.40]

The long-term course of MDD is highly variable but in approximately half of patients evolves into a chronic, relapsing illness. Untreated, a major depressive episode typically lasts about 6-12 months before resolving spontaneously. The emotional, physical, and social toll exacted during these months of depression can be tremendous. When the illness remits, most patients are able to function at their previous level however, 20% experience only a partial remission with persistent depressive symptoms that may last months or even years. [Pg.41]

Antidepressants. In the early 1980s, the recognition that depression is a frequent comorbid feature of BN coupled with the observation that appetite changes are a common feature of depression led researchers to evaluate antidepressant treatment for BN. Since that time, a series of controlled studies have demonstrated efficacy for a wide assortment of antidepressants including the TCAs imipramine (Tofranil) and desipramine (Norpramin), the MAOl phenelzine (Nardil), the SSRl fluoxetine (Prozac), and the atypical antidepressants trazodone (Desyrel) and bupropion (Wellbutrin). Overall, approximately two-thirds of antidepressant-treated patients with bulimia experience symptomatic improvement while nearly one-third achieves complete remission of binging and purging. In addition, the improvement in the symptoms of BN is not dependent on the presence of comorbid depression. [Pg.221]

Approximately 30 years ago, Schildkraut postulated that noradrenaline may play a pivotal role in the aetiology of depression. Evidence in favour of this hypothesis was provided by the observation that the antihypertensive drug reserpine, which depletes both the central and peripheral vesicular stores of catecholamines such as noradrenaline, is likely to precipitate depression in patients in remission. The experimental drug alpha-methyl-paratyrosine that blocks the synthesis of noradrenaline by inhibiting the rate-limiting enzyme tyrosine hydroxylase was also shown to precipitate depression in patients during remission. While such findings are only indirect indicators that noradrenaline plays an important role in human behaviour, and may be defective in depression, more direct evidence is needed to substantiate the hypothesis. The most obvious approach would be to determine the concentration of noradrenaline and/or its major central... [Pg.155]

The possibility of suicide in depressed patients remains during treatment and until significant remission occurs. Patients should not have easy access to large... [Pg.1039]

Maintenance Use the lowest dose that maintains remission. Although it is not known how long the patient should remain on bupropion, acute episodes of depression generally require several months or longer of treatment. [Pg.1053]


See other pages where Depression remission is mentioned: [Pg.190]    [Pg.192]    [Pg.425]    [Pg.428]    [Pg.429]    [Pg.557]    [Pg.580]    [Pg.592]    [Pg.607]    [Pg.611]    [Pg.69]    [Pg.128]    [Pg.59]    [Pg.124]    [Pg.380]    [Pg.381]    [Pg.680]    [Pg.779]    [Pg.10]    [Pg.17]    [Pg.122]    [Pg.290]    [Pg.62]    [Pg.66]    [Pg.146]    [Pg.71]    [Pg.84]    [Pg.1060]   
See also in sourсe #XX -- [ Pg.42 , Pg.142 , Pg.143 , Pg.147 , Pg.148 , Pg.148 ]




SEARCH



Depression partial remission

Major depressive disorder remission

© 2024 chempedia.info